Selenium supplementation and prostate cancer mortality

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Kenfield, Stacey A ^a,b   Van Blarigan, Erin L ^a,c   DuPre, Natalie ^b   Stampfer, Meir J ^b,d   Giovannucci, Edward L ^b,d   Chan, June M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIVITAMIN; SELENIUM; TRACE ELEMENT;

AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER MORTALITY; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DIET SUPPLEMENTATION; FOLLOW UP; HEALTH PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT RISK; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; COMPARATIVE STUDY; DIETARY SUPPLEMENT; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK FACTOR; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIETARY SUPPLEMENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS; SELENIUM; TRACE ELEMENTS;

EID: 84930443314     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju360     Document Type: Article

References (38)

1. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276(24):1957-1963.
2. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91(7):608-612.
3. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39-51.
4. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-1556.
5. Kristal AR, Darke AK, Morris JS, et al. Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk. J Natl Cancer Inst. 2014;106(3):djt456 doi:10.1093/jnci/djt456.
6. Waters DJ, Shen S, Glickman LT, et al. Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model. Carcinogenesis. 2005;26(7):1256-1262.
7. Chiang EC, Shen S, Kengeri SS, et al. Defining the Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis. Dose Response. 2009;8(3):285-300.
8. Feskanich D, Rimm EB, Giovannucci EL, et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc. 1993;93(7):790-796.
9. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large singleinstitution experience with radical prostatectomy and externalbeam radiotherapy. J Clin Oncol. 2002;20(16):3376-3385.
10. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61(2):365-369.
11. Roach M, 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-974.
12. Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. Aug 1 2006;65(5):1487-1493.
13. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994;140(11):1016-1019.
14. Shamberger RJ, Tytko SA, Willis CE. Antioxidants and cancer. Part VI. Selenium and age-adjusted human cancer mortality. Archives of environmental health. 1976;31(5):231-235.
15. Stratton MS, Reid ME, Schwartzberg G, et al. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the 'Watchful Waiting' Study. Anticancer Drugs. 2003;14(8):595-600.
16. Stratton MS, Algotar AM, Ranger-Moore J, et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila). 2010;3(8):1035-1043.
17. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst. 1998;90(16):1219-1224.
18. Geybels MS, Verhage BA, van Schooten FJ, Goldbohm RA, van den Brandt PA. Advanced prostate cancer risk in relation to toenail selenium levels. J Natl Cancer Inst. 2013;105(18):1394-1401.
19. Hurst R, Hooper L, Norat T, et al. Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr. 2012;96(1):111-122.
20. Lawson KA, Wright ME, Subar A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst. 2007;99(10):754-764.
21. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the Health Professionals Follow-up Study. Int J Cancer. 2007;121(7):1571-1578.
22. Zu K, Giovannucci E. Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control. 2009;20(10):1799-1810.
23. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305(24):2548-2555.
24. Rikiishi H. Apoptotic cellular events for selenium compounds involved in cancer prevention. J Bioenerg Biomembr. 2007;39(1):91-98.
25. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1171-1182.
26. Xiang N, Zhao R, Zhong W. Sodium selenite induces apoptosis by generation of superoxide via the mitochondrialdependent pathway in human prostate cancer cells. Cancer Chemother Pharmacol. 2009;63(2):351-362.
27. Sarveswaran S, Liroff J, Zhou Z, Nikitin AY, Ghosh J. Selenite triggers rapid transcriptional activation of p53, and p53-mediated apoptosis in prostate cancer cells: Implication for the treatment of early-stage prostate cancer. Int J Oncology. 2010;36(6):1419-1428.
28. Zeng H, Combs GF Jr. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem. 2008;19(1):1-7.
29. Webber MM, Perez-Ripoll EA, James GT. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun. 1985;130(2):603-609.
30. Redman C, Scott JA, Baines AT, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. 1998;125(1-2):103-110.
31. Sinha R, Pinto JT, Facompre N, Kilheffer J, Baatz JE, El-Bayoumy K. Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells. Nutr Cancer. 2008;60(2):267-275.
32. Lindshield BL, Ford NA, Canene-Adams K, Diamond AM, Wallig MA, Erdman JW Jr. Selenium, but not lycopene or vitamin E, decreases growth of transplantable dunning R3327-H rat prostate tumors. PLoS One. 2010;5(4):e10423.
33. Corcoran NM, Najdovska M, Costello AJ. Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol. 2004;171(2 Pt 1):907-910.
34. Wang Z, Hu H, Li G, et al. Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density. Int J Cancer. 2008;122(1):15-24.
35. de Rosa V, Erkekoglu P, Forestier A, et al. Low doses of selenium specifically stimulate the repair of oxidative DNA damage in LNCaP prostate cancer cells. Free Radical Res. 2012;46(2):105-116.
36. Kandas NO, Randolph C, Bosland MC. Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations. Nutr Cancer. 2009;61(2):251-264.
37. Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256-1268.
38. Willett WC, Buzzard IM. Foods and Nutrients. In: Willett WC, ed. Nutritional Epidemiology. 2nd ed. New York, NY: Oxford University Press; 1998:18-32.